Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001 Apr;14(2):430-45.
doi: 10.1128/CMR.14.2.430-445.2001.

Vaccination strategies for mucosal immune responses

P L Ogra  1 , H Faden, R C Welliver
Affiliations
Review

Vaccination strategies for mucosal immune responses

P L Ogra et al. Clin Microbiol Rev. 2001 Apr.

Erratum in

  • Clin Microbiol Rev 2001 Jul;14(3):641

Abstract

Mucosal administration of vaccines is an important approach to the induction of appropriate immune responses to microbial and other environmental antigens in systemic sites and peripheral blood as well as in most external mucosal surfaces. The development of specific antibody- or T-cell-mediated immunologic responses and the induction of mucosally induced systemic immunologic hyporesponsiveness (oral or mucosal tolerance) depend on complex sets of immunologic events, including the nature of the antigenic stimulation of specialized lymphoid structures in the host, antigen-induced activation of different populations of regulatory T cells (Th1 versus Th2), and the expression of proinflammatory and immunoregulatory cytokines. Availability of mucosal vaccines will provide a painless approach to deliver large numbers of vaccine antigens for human immunization. Currently, an average infant will receive 20 to 25 percutaneous injections for vaccination against different childhood infections by 18 months of age. It should be possible to develop for human use effective, nonliving, recombinant, replicating, transgenic, and microbial vector- or plant-based mucosal vaccines to prevent infections. Based on the experience with many dietary antigens, it is also possible to manipulate the mucosal immune system to induce systemic tolerance against environmental, dietary, and possibly other autoantigens associated with allergic and autoimmune disorders. Mucosal immunity offers new strategies to induce protective immune responses against a variety of infectious agents. Such immunization may also provide new prophylactic or therapeutic avenues in the control of autoimmune diseases in humans.

PubMed Disclaimer

References

    1. Abraham S N, Sharon N, Ofek I. Adhesion of bacteria to mucosal surfaces. In: Ogra P L, Mestecky J, Lamm M E, Strober W, Bienenstock J, McGhee J R, editors. Mucosal immunology. 2nd ed. New York, N.Y: Academic Press; 1999. pp. 31–42.
    1. Adams S E, Dawson K M, Gull K, Klingsman S M, Klingsman A J. The expression of hybrid HIV:Ty virus-like particles in yeast. Nature. 1987;329:68–70. - PubMed
    1. Aggarwal A, Kumar S, Jaffe R, Hone D, Gross M, Sadoff J. Oral salmonella: malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells. J Exp Med. 1990;172:1083–1090. - PMC - PubMed
    1. Aichele P, Brduscha-Riem K, Zinkernagel R M, Hengartner H, Pircher H. T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med. 1995;182:261–266. - PMC - PubMed
    1. Al-Sabbagh A, Nelson P, Sobel R A, Weiner H L. Antigen-driven peripheral immune tolerance: suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen. Cell Immunol. 1996;171:111–119. - PubMed